A randomized controlled trial of precision bezlotoxumab treatment for Clostridioides difficile infection.

Summary

A two-stage program derived and validated the BEYOND risk score and then tested precision bezlotoxumab in a double-blind RCT. In high-risk CDI patients, bezlotoxumab plus standard care significantly reduced the composite of organ dysfunction, relapse, or death versus placebo (31.8% vs 72.7%).

Key Findings

• The BEYOND score integrating clinical, cytokine, genetic, and microbiome features achieved 84.6% sensitivity and 95.8% specificity for unfavorable CDI outcomes.
• In a double-blind RCT of 44 high-risk CDI patients, bezlotoxumab plus standard care reduced the composite endpoint to 31.8% vs 72.7% with placebo (p=0.015).
• Trial registration included NCT02573571, NCT04725123, and NCT05304715, supporting methodological transparency.

Clinical Implications

Risk-stratified use of bezlotoxumab may prevent organ dysfunction, relapse, and death in CDI. Implementation will require external validation of the BEYOND score, availability of biomarker/microbiome testing, and assessment of cost-effectiveness.

Limitations

• Small sample size in the RCT limits precision and generalizability
• Risk score requires external validation and may be susceptible to overfitting

Future Directions

Conduct larger, multicenter trials to validate the BEYOND score and bezlotoxumab benefit, evaluate real-world implementation, and assess cost-effectiveness.